Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin Dreesen

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
The AAPS Journal|February 1, 2024
Agreement Between a Colorimetric Assay and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Quantifying Paracetamol Plasma ConcentrationsAngela Elma Edwina, Erwin Dreesen, Julie Hias, et al.
Pharmaceutics|February 26, 2025
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel DiseaseAndres J Yarur, Thierry Dervieux, Ryan Ungaro, et al.
Pharmaceutics|July 27, 2022
Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in AdultsHeleen Gastmans, Erwin Dreesen, Sebastian G Wicha, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 23, 2021
Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic AnalysisSabrina De Winter, Reinier van Hest, Erwin Dreesen, et al.
Pharmaceutics|October 23, 2021
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic ModelJurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 29, 2020
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical RemissionJurij Hanžel, Jurij Zdovc, Tina Kurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2019
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's DiseaseErwin Dreesen, Filip Baert, David Laharie, et al.
Clinical Pharmacology and Therapeutics|August 10, 2023
TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde-Evoked Dermal Blood Flow Increase: Translational Proof of PharmacologyDorien Bamps, Anthony James Blockeel, Erwin Dreesen, et al.
Journal of Crohn'S & Colitis|March 24, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitisEmmanuel Niyigena, Yannick Hoffert, Waqqas Afif, et al.
Frontiers in Immunology|June 27, 2022
Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune DisordersE Sally Ward, Deborah Gelinas, Erwin Dreesen, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
The AAPS Journal|February 1, 2024
Agreement Between a Colorimetric Assay and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Quantifying Paracetamol Plasma ConcentrationsAngela Elma Edwina, Erwin Dreesen, Julie Hias, et al.
Pharmaceutics|February 26, 2025
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel DiseaseAndres J Yarur, Thierry Dervieux, Ryan Ungaro, et al.
Pharmaceutics|July 27, 2022
Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in AdultsHeleen Gastmans, Erwin Dreesen, Sebastian G Wicha, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 23, 2021
Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic AnalysisSabrina De Winter, Reinier van Hest, Erwin Dreesen, et al.
Pharmaceutics|October 23, 2021
Ustekinumab Dosing Individualization in Crohn's Disease Guided by a Population Pharmacokinetic-Pharmacodynamic ModelJurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 29, 2020
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical RemissionJurij Hanžel, Jurij Zdovc, Tina Kurent, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2019
Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's DiseaseErwin Dreesen, Filip Baert, David Laharie, et al.
Clinical Pharmacology and Therapeutics|August 10, 2023
TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde-Evoked Dermal Blood Flow Increase: Translational Proof of PharmacologyDorien Bamps, Anthony James Blockeel, Erwin Dreesen, et al.
Journal of Crohn'S & Colitis|March 24, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitisEmmanuel Niyigena, Yannick Hoffert, Waqqas Afif, et al.
Frontiers in Immunology|June 27, 2022
Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune DisordersE Sally Ward, Deborah Gelinas, Erwin Dreesen, et al.
Pageof 11